Skip to content

Amylyx Pharmaceuticals, Inc. AMLX Other Non-Current Assets

Other Non-Current Assets at other companies

MBX Biosciences, Inc. logo
MBX Biosciences, Inc.MBX
$579K+1,058%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$33K-28.3%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$7.76M+751%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$4.9M-65.4%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$751K+130%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$2.52M-64.8%

Other financials

Income statement

See full
Revenue-
Gross profit-
Operating income-$43.8M-15.8%
Net income-$41.3M-15.0%
EPS (diluted)-$0.37+11.9%

Balance sheet

See full
Cash & equivalents$229.1M+283%
Total debt$5.6M+307%
Total equity$273.2M+35.6%
Total assets$293.6M+33.7%

Cash flow

See full
Operating cash flow-$36.9M+7.4%
CapEx$86.0K+330%
Free cash flow-$28.0M+52.6%

Valuation

See full
Market cap$1.82B+390%
Enterprise value$1.6B+414%

Profitability

See full
Gross margin100%+6.9pp
Operating margin-47,349.8%-47,409pp
Net margin-45,096.2%-45,152pp
FCF margin-39,826.7%-39,847pp

Returns & leverage

See full
Return on equity-63.3%-12.2pp
Debt / equity0.0×
Current ratio17.9×+5.8×

Where this comes from

Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amylyx Pharmaceuticals, Inc.'s other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amylyx Pharmaceuticals, Inc.'s other non-current assets?
Amylyx Pharmaceuticals, Inc. (AMLX) reported other non-current assets of $2.5M in Q1 2026.
How has Amylyx Pharmaceuticals, Inc.'s other non-current assets changed year-over-year?
Amylyx Pharmaceuticals, Inc.'s other non-current assets increased by 22627.3% year-over-year, from $11K to $2.5M.
What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s other non-current assets?
Over 3 years (2022 to 2025), Amylyx Pharmaceuticals, Inc.'s other non-current assets has grown at a 75.0% compound annual growth rate (CAGR), from $466K to $2.5M.
What does other non-current assets mean?
Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.